Maria Kefalas and Patrick Carr, Founders. Ms. Kefalas is a professor in the Department of Sociology at Saint Joseph's University and the late Mr. Carr was an associate professor and director of the Criminal Justice Program at Rutgers University-New Brunswick. Both earned doctorates in Sociology from the University of Chicago. 

Mr. Bliamptis is a Managing Director of Weathergage Capital, which he founded in 2006. He began his investment career in the Treasurer’s Office at the Massachusetts Institute of Technology, where he focused on the endowment’s venture capital investments. He holds degrees in Electrical Engineering from MIT and an MBA from The Wharton School, University of Pennsylvania.

Dr. Kaiser is a rheumatologist in private practice in the Washington D.C. area. Prior to focusing full-time on clinical practice, she was on the faculty of the Division of Rheumatology at the University of California, San Francisco (UCSF) where her research focused on genetic risk factors of blood clots in lupus patients.

Dr. Shenker is a pediatric physician-scientist with expertise in cell signaling, disease pathophysiology and genotype-phenotype relationships, gene therapy, and the clinical development of novel treatments for rare metabolic and neurological diseases, including metachromatic leukodystrophy and other lysosomal storage disorders.He has over 20 years of experience in academic, biotech and pharmaceutical industry settings, most recently as Vice President, GlaxoSmithKline Rare Diseases. He currently works as an independent consultant.

Dr. Waldman is Attending Physician, Assistant Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania and serves as Medical Director of the Leukodystrophy Center of Excellence.

​

​
 

Dr. Milne is the President and CEO of Catabasis, a Cambridge, MA based biotech.  Prior to founding Catabasis, Dr. Milne worked as the head of discovery biology at Sirtris Pharmaceuticals and a served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center. She holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.

Dr. Vanderver is a Jacob A. Kamens Endowed Chair in Neurological Disorders and Translational NeuroTherapeutics at The Children’s Hospital of Philadelphia. Dr. Vanderver is an international leader in the study of leukodystrophies.